Study shows economic benefit of EECP (enhanced external counterpulsation):
This article was originally published in Clinica
Executive Summary
Use of Vasomedical's enhanced external counterpulsation (EECP) therapy in patients with chronic, refractory angina results in a significant reduction in the number of inpatient hospital days in the first year after treatment, according to an Irish study presented at the British Cardiac Society meeting in May. The study was the first to demonstrate an economic benefit of EECP. Data from a US study presented at the same meeting supported the use of EECP as initial treatment in patients with angina or chest pain.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.